Class information for:
Level 1: INFLIXIMAB//CROHNS DISEASE//MUCOSAL HEALING

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1645 2557 43.5 87%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
380 3       CROHNS DISEASE//ULCERATIVE COLITIS//INFLAMMATORY BOWEL DISEASE 31889
52 2             CROHNS DISEASE//ULCERATIVE COLITIS//INFLAMMATORY BOWEL DISEASE 29969
1645 1                   INFLIXIMAB//CROHNS DISEASE//MUCOSAL HEALING 2557

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INFLIXIMAB authKW 1270059 21% 20% 534
2 CROHNS DISEASE authKW 896606 36% 8% 908
3 MUCOSAL HEALING authKW 704393 5% 50% 119
4 ADALIMUMAB authKW 589476 9% 21% 237
5 VEDOLIZUMAB authKW 540946 2% 85% 53
6 LOSS OF RESPONSE authKW 359181 1% 79% 38
7 ULCERATIVE COLITIS authKW 356466 20% 6% 512
8 INFLAMMATORY BOWEL DISEASE authKW 331689 21% 5% 544
9 CERTOLIZUMAB PEGOL authKW 256022 2% 46% 47
10 JOURNAL OF CROHNS & COLITIS journal 232852 5% 14% 140

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Gastroenterology & Hepatology 146278 72% 1% 1831
2 Pharmacology & Pharmacy 2116 19% 0% 480
3 Medicine, General & Internal 447 8% 0% 198
4 Nutrition & Dietetics 150 3% 0% 68
5 Pediatrics 140 4% 0% 92
6 Medicine, Research & Experimental 55 3% 0% 76
7 Immunology 31 4% 0% 94
8 Health Care Sciences & Services 18 1% 0% 26
9 Health Policy & Services 15 1% 0% 17
10 Medical Laboratory Technology 15 1% 0% 17

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INFLAMMATORY BOWEL DIS 190933 5% 13% 125
2 ROBARTS CLIN TRIALS 190027 1% 43% 37
3 GASTROENTEROL 144031 37% 1% 957
4 U954 117748 2% 19% 52
5 IBD 98522 2% 17% 48
6 UNIV HOSP NANCY 91734 1% 27% 28
7 NANCY UNIV HOSP 89776 1% 40% 19
8 THER EUT DIAGNOST ANTIBODIES 87943 1% 39% 19
9 INFLAMMATORY BOWEL DIS CLIN 76966 2% 16% 40
10 INSERM U954 69189 1% 29% 20

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF CROHNS & COLITIS 232852 5% 14% 140
2 FALK SYMPOSIUM 202110 9% 8% 218
3 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 81204 8% 3% 209
4 INFLAMMATORY BOWEL DISEASES 70283 2% 10% 62
5 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 30896 3% 3% 80
6 DIGESTIVE DISEASES 29799 3% 4% 66
7 REVIEWS IN GASTROENTEROLOGICAL DISORDERS 17542 0% 15% 10
8 DIGESTIVE AND LIVER DISEASE 12615 2% 2% 53
9 GUT 12088 4% 1% 98
10 AMERICAN JOURNAL OF GASTROENTEROLOGY 11143 4% 1% 104

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 INFLIXIMAB 1270059 21% 20% 534 Search INFLIXIMAB Search INFLIXIMAB
2 CROHNS DISEASE 896606 36% 8% 908 Search CROHNS+DISEASE Search CROHNS+DISEASE
3 MUCOSAL HEALING 704393 5% 50% 119 Search MUCOSAL+HEALING Search MUCOSAL+HEALING
4 ADALIMUMAB 589476 9% 21% 237 Search ADALIMUMAB Search ADALIMUMAB
5 VEDOLIZUMAB 540946 2% 85% 53 Search VEDOLIZUMAB Search VEDOLIZUMAB
6 LOSS OF RESPONSE 359181 1% 79% 38 Search LOSS+OF+RESPONSE Search LOSS+OF+RESPONSE
7 ULCERATIVE COLITIS 356466 20% 6% 512 Search ULCERATIVE+COLITIS Search ULCERATIVE+COLITIS
8 INFLAMMATORY BOWEL DISEASE 331689 21% 5% 544 Search INFLAMMATORY+BOWEL+DISEASE Search INFLAMMATORY+BOWEL+DISEASE
9 CERTOLIZUMAB PEGOL 256022 2% 46% 47 Search CERTOLIZUMAB+PEGOL Search CERTOLIZUMAB+PEGOL
10 DEEP REMISSION 112097 1% 72% 13 Search DEEP+REMISSION Search DEEP+REMISSION

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 STEENHOLDT, C , (2016) PERSONALIZED THERAPY WITH TNF-INHIBITORS IN CROHN'S DISEASE: OPTIMIZING TREATMENT OUTCOMES BY MONITORING DRUG LEVELS AND ANTI-DRUG ANTIBODIES.DANISH MEDICAL JOURNAL. VOL. 63. ISSUE 8. P. - 277 71% 0
2 STEENHOLDT, C , BENDTZEN, K , BRYNSKOV, J , AINSWORTH, MA , (2016) OPTIMIZING TREATMENT WITH TNF INHIBITORS IN INFLAMMATORY BOWEL DISEASE BY MONITORING DRUG LEVELS AND ANTIDRUG ANTIBODIES.INFLAMMATORY BOWEL DISEASES. VOL. 22. ISSUE 8. P. 1999 -2015 177 78% 3
3 DING, NS , HART, A , DE CRUZ, P , (2016) SYSTEMATIC REVIEW: PREDICTING AND OPTIMISING RESPONSE TO ANTI-TNF THERAPY IN CROHN'S DISEASE - ALGORITHM FOR PRACTICAL MANAGEMENT.ALIMENTARY PHARMACOLOGY & THERAPEUTICS. VOL. 43. ISSUE 1. P. 30 -51 98 82% 13
4 PAPAMICHAEL, K , GILS, A , RUTGEERTS, P , LEVESQUE, BG , VERMEIRE, S , SANDBORN, WJ , VANDE CASTEELE, N , (2015) ROLE FOR THERAPEUTIC DRUG MONITORING DURING INDUCTION THERAPY WITH TNF ANTAGONISTS IN IBD: EVOLUTION IN THE DEFINITION AND MANAGEMENT OF PRIMARY NONRESPONSE.INFLAMMATORY BOWEL DISEASES. VOL. 21. ISSUE 1. P. 182 -197 135 85% 11
5 DULAI, PS , SIEGEL, CA , COLOMBEL, JF , SANDBORN, WJ , PEYRIN-BIROULET, L , (2014) SYSTEMATIC REVIEW: MONOTHERAPY WITH ANTITUMOUR NECROSIS FACTOR ALPHA AGENTS VERSUS COMBINATION THERAPY WITH AN IMMUNOSUPPRESSIVE FOR IBD.GUT. VOL. 63. ISSUE 12. P. 1843 -1853 135 85% 7
6 BEN-HORIN, S , CHOWERS, Y , (2014) TAILORING ANTI-TNF THERAPY IN IBD: DRUG LEVELS AND DISEASE ACTIVITY.NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY. VOL. 11. ISSUE 4. P. 243-255 95 79% 33
7 GISBERT, JP , MARIN, AC , MCNICHOLL, AG , CHAPARRO, M , (2015) SYSTEMATIC REVIEW WITH META-ANALYSIS: THE EFFICACY OF A SECOND ANTI-TNF IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHOSE PREVIOUS ANTI-TNF TREATMENT HAS FAILED.ALIMENTARY PHARMACOLOGY & THERAPEUTICS. VOL. 41. ISSUE 7. P. 613 -623 62 93% 36
8 BILLIET, T , RUTGEERTS, P , FERRANTE, M , VAN ASSCHE, G , VERMEIRE, S , (2014) TARGETING TNF-ALPHA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.EXPERT OPINION ON BIOLOGICAL THERAPY. VOL. 14. ISSUE 1. P. 75 -101 100 66% 34
9 STEENHOLDT, C , (2013) USE OF INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODY MEASUREMENTS TO EVALUATE AND OPTIMIZE EFFICACY AND SAFETY OF INFLIXIMAB MAINTENANCE THERAPY IN CROHN'S DISEASE.DANISH MEDICAL JOURNAL. VOL. 60. ISSUE 4. P. - 122 68% 8
10 COHEN, LB , NANAU, RM , DELZOR, F , NEUMAN, MG , (2014) BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE.TRANSLATIONAL RESEARCH. VOL. 163. ISSUE 6. P. 533-556 80 87% 21

Classes with closest relation at Level 1


Rank Class id link
1 16188 TOXIC MEGACOLON//SEVERE ULCERATIVE COLITIS//COLECTOMY
2 13180 FECAL CALPROTECTIN//CALPROTECTIN//FAECAL CALPROTECTIN
3 5894 INFLAMMATORY BOWEL DISEASE//CROHNS DISEASE//ULCERATIVE COLITIS
4 7630 STRICTUREPLASTY//CROHNS DISEASE//ILEOCOLIC RESECTION
5 4124 ULCERATIVE COLITIS//CROHNS DISEASE//INFLAMMATORY BOWEL DISEASE
6 4564 MESALAZINE//5 AMINOSALICYLIC ACID//MESALAMINE
7 16155 INFLIXIMAB//DRUG INDUCED LUPUS//ADALIMUMAB
8 6410 INFLAMMATORY BOWEL DISEASE//IS 741//ULCERATIVE COLITIS
9 3737 6 MERCAPTOPURINE//THIOPURINE METHYLTRANSFERASE//AZATHIOPRINE
10 23148 LEUKOCYTAPHERESIS//GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS//ADACOLUMN

Go to start page